DYADIC INTERNATIONAL INC. - COMMON STOCK

Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

12 May 2022 16:00:00 By Nasdaq GlobeNewswire

Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

11 May 2022 08:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”

09 May 2022 08:30:00 By Nasdaq GlobeNewswire

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

28 Apr 2022 16:30:00 By Nasdaq GlobeNewswire

Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform

13 Apr 2022 08:52:30 By Nasdaq GlobeNewswire

Dyadic International to Present at Upcoming Scientific Medical Meetings

04 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Dyadic Reports 2021 Year End Results and Recent Company Progress

29 Mar 2022 16:00:00 By Nasdaq GlobeNewswire

Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022

15 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

10 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

07 Feb 2022 08:30:01 By Nasdaq GlobeNewswire

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

20 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

22 Dec 2021 09:12:47 By Nasdaq GlobeNewswire

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

17 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

10 Nov 2021 16:00:00 By Nasdaq GlobeNewswire

Dyadic Appoints Chief Business Officer to Executive Leadership Team

09 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

27 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

10 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

11 Aug 2021 08:35:40 By Nasdaq GlobeNewswire

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

27 Jul 2021 08:20:00 By Nasdaq GlobeNewswire

Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

28 Jun 2021 08:30:00 By Nasdaq GlobeNewswire